#6 - Inovio (NASDAQ:INO)
Inovio (NASDAQ:INO) is a cautionary tale about why being first is not necessarily best when it comes to a vaccine. Inovio was one of the first companies to announce that it had a potential vaccine for the coronavirus. And Inovio has received a $5 million grant from CEPI to fund its preclinical and phase 1 clinial testing of its vaccine. Inovio expects the trial to start in April and is forecasting one million doses to be available by the end of the year.
That’s the good news. The more troubling news for investors is that the nature of vaccines is that not all of them are effective. And, even if they are, there’s no guarantee that Inovio will be the first to market. Both of these are headwinds on the stock. However, investors are buying Inovio because it is a growth stock. And it does have other drugs in its pipeline.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Read More - Current Price
- $6.69
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $44.00 (557.7% Upside)
